Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: Amneal vs. Apellis - A Decade of Change

__timestampAmneal Pharmaceuticals, Inc.Apellis Pharmaceuticals, Inc.
Wednesday, January 1, 2014846150002908166
Thursday, January 1, 20151096790006356782
Friday, January 1, 20161187570004303743
Sunday, January 1, 201710904600010463151
Monday, January 1, 201823043500022639184
Tuesday, January 1, 201928959800067046483
Wednesday, January 1, 2020326727000139401000
Friday, January 1, 2021365504000176771000
Saturday, January 1, 2022399700000277163000
Sunday, January 1, 2023429675000500815000
Loading chart...

Unleashing insights

SG&A Expenses: A Tale of Two Pharmaceuticals

In the competitive landscape of pharmaceuticals, understanding the financial dynamics is crucial. Over the past decade, Amneal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, reflecting a strategic expansion and increased operational costs. In contrast, Apellis, starting with a modest base, witnessed an exponential rise, culminating in a 17,000% increase by 2023. This dramatic growth underscores Apellis's aggressive market penetration and investment in administrative capabilities. Notably, by 2023, Apellis's SG&A expenses surpassed Amneal's, highlighting a pivotal shift in financial strategy. These trends offer a window into the evolving priorities and market strategies of these pharmaceutical giants, providing valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025